All Studies Meta Analysis Recent:

Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis

Srinivasan et al., American Heart Journal Plus: Cardiology Research and Practice, doi:10.1016/j.ahjo.2022.100191 (meta analysis)

Srinivasan et al., Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis, American Heart Journal Plus: Cardiology Research and Practice, doi:10.1016/j.ahjo.2022.100191 (meta analysis)

Aug 2022 Source PDF

Twitter
Facebook

All Studies Meta

Meta analysis of 14 studies with 164,539 patients, showing lower mortality with aspirin.

Currently there are 66 aspirin studies and meta analysis shows:

Outcome	Improvement
Mortality	11% lower [4‑16%]
Ventilation	5% lower [-6‑15%]
ICU admission	4% lower [-13‑18%]
Hospitalization	2% higher [-4‑8%]
Cases	10% fewer [-6‑24%]

Important missing comments or errors? Let us know.

risk of death, 29.0% lower, RR 0.71, p < 0.001.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Srinivasan et al., 11 Aug 2022, peer-reviewed, 8 authors.

Contact: kayani@bcm.edu.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Aspirin All

Aspirin use is associated with decreased inpatient mortality in patients with COVID-19: A meta-analysis

Aswin Srinivasan, Jonathan Brown, Pavitra Parimala Krishnamani, Brendon Cornett, MD Ramesh Babu Kesavan, Siva T Sarva, Syed Arman Raza, Waleed Tallat Kayani

American Heart Journal Plus: Cardiology Research and Practice, doi:10.1016/j.ahjo.2022.100191

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Declaration of interests ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. ☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: . J o u r n a l P r e -p r o o f

References

Ahmed, Merrell, Ismail, Rationales and uncertainties for aspirin use in COVID-19: a narrative review, Fam Med Community Health, doi:10.1136/fmch-2020-000741

Bianconi, Violi, Fallarino, Is acetylsalicylic acid a safe and potentially useful choice for adult patients with COVID-19?, Drugs

Chow, Khanna, Kethirddy, Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019, Anesth Analg

Chow, Rahnavard, Gomberg-Maitland, o u r n a l P r e -p r o o f Journal Pre-proof

Chow, Yin, Yamane, Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis, J Thromb Haemost, doi:10.1111/jth.15517

Investigators, Association of Early Aspirin Use with In-Hospital Mortality in Patients with Moderate COVID-19, JAMA Netw Open, doi:10.1001/jamanetworkopen.2022.3890

J O U R N A L P R E, -p r o o f

Klok, Kruip, Van Der Meer, Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis, Thromb Res, doi:10.1016/j.thromres.2020.04.041

Mcfadyen, Stevens, Peter, The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications, Circ Res, doi:10.1161/CIRCRESAHA.120.317447

Mehta, Mcauley, Brown, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet

Santoro, Nuñez-Gil, Vitale, Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry, Heart, doi:10.1136/heartjnl-2021-319552

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit